Forte Biosciences (NASDAQ:FBRX) Lowered to Hold Rating by Brookline Capital Markets

Posted by Geri Gentry on Jul 29th, 2026

Brookline Capital Markets downgraded shares of Forte Biosciences (NASDAQ:FBRX – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday morning,Zacks.com reports.

Several other equities analysts also recently issued reports on FBRX. Evercore set a $77.00 price objective on shares of Forte Biosciences in a report on Monday. TD Cowen cut shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Forte Biosciences in a research report on Wednesday, July 8th. Wall Street Zen downgraded shares of Forte Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Barclays lowered shares of Forte Biosciences from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $74.00 to $77.00 in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $72.50.

Check Out Our Latest Research Report on FBRX

Forte Biosciences Price Performance

Shares of FBRX stock opened at $76.65 on Monday. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -16.52 and a beta of 2.85. The stock has a 50 day simple moving average of $28.43 and a 200-day simple moving average of $28.59. Forte Biosciences has a 1-year low of $9.10 and a 1-year high of $76.68.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.08). Analysts anticipate that Forte Biosciences will post -4.27 earnings per share for the current fiscal year.

Institutional Trading of Forte Biosciences

Large investors have recently bought and sold shares of the business. Global Retirement Partners LLC purchased a new position in Forte Biosciences in the 4th quarter worth approximately $27,000. Bank of America Corp DE grew its position in shares of Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock valued at $47,000 after purchasing an additional 3,103 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Forte Biosciences in the third quarter valued at approximately $161,000. Jane Street Group LLC acquired a new stake in shares of Forte Biosciences in the fourth quarter valued at approximately $228,000. Finally, Citadel Advisors LLC purchased a new position in Forte Biosciences during the third quarter worth approximately $234,000. Hedge funds and other institutional investors own 77.63% of the company’s stock.

Forte Biosciences News Roundup

Here are the key news stories impacting Forte Biosciences this week:

Positive Sentiment: argenx will acquire all outstanding Forte shares for $77 in cash, giving investors a clear deal-value reference and significantly repricing FBRX above its pre-announcement level. The acquisition also gives argenx access to Forte’s experimental autoimmune therapy FB102, strengthening its immunology pipeline. Reuters article
Positive Sentiment: The all-cash structure reduces exposure to biotechnology development risk for Forte shareholders, while the premium and strategic interest from argenx provide support for the current valuation. Proactive Investors article
Neutral Sentiment: FBRX trading volume has been substantially above its average, consistent with merger-related positioning. A significant increase in put-option activity also indicates that some traders are hedging against deal or market risk rather than simply betting on further gains.
Negative Sentiment: Several shareholder-rights law firms, including Kahn Swick & Foti, are investigating whether the $77 consideration and sale process adequately protect shareholders. Similar investigations by Halper Sadeh, Ademi and Monteverde could create litigation, delay or renegotiation risk, although these announcements do not by themselves indicate that the transaction will fail. Kahn Swick & Foti investigation

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.